Q3 Earnings Forecast for Cencora Issued By Leerink Partnrs

Cencora, Inc. (NYSE:COR) – Stock analysts at Leerink Partnrs increased their Q3 2025 earnings per share estimates for Cencora in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings per share of $3.89 for the quarter, up from their previous forecast of $3.87. The consensus estimate for Cencora’s current full-year earnings is $15.32 per share. Leerink Partnrs also issued estimates for Cencora’s FY2025 earnings at $15.52 EPS, FY2026 earnings at $17.17 EPS and FY2027 earnings at $19.01 EPS.

A number of other research analysts have also recently commented on the company. Robert W. Baird boosted their price objective on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Mizuho began coverage on Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective on the stock. Wells Fargo & Company lifted their target price on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 29th. Barclays lifted their target price on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Finally, Evercore ISI lifted their target price on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $277.90.

Cencora Price Performance

Shares of Cencora stock opened at $246.11 on Friday. The business’s fifty day moving average price is $239.08 and its 200 day moving average price is $236.51. The stock has a market capitalization of $47.57 billion, a P/E ratio of 32.77, a PEG ratio of 1.59 and a beta of 0.49. Cencora has a twelve month low of $214.77 and a twelve month high of $262.26. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 266.62% and a net margin of 0.51%.

Institutional Trading of Cencora

Several large investors have recently added to or reduced their stakes in COR. Insight Wealth Strategies LLC increased its stake in shares of Cencora by 124.6% in the fourth quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock worth $4,549,000 after acquiring an additional 11,232 shares during the last quarter. Cerity Partners LLC boosted its holdings in Cencora by 10.1% in the third quarter. Cerity Partners LLC now owns 39,457 shares of the company’s stock worth $8,881,000 after purchasing an additional 3,610 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. boosted its holdings in Cencora by 71.1% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company’s stock worth $1,583,000 after purchasing an additional 2,928 shares in the last quarter. Sylvest Advisors LLC bought a new stake in Cencora in the fourth quarter worth $1,105,000. Finally, Portfolio Design Labs LLC bought a new stake in Cencora in the third quarter worth $1,404,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Cencora

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the sale, the chairman now directly owns 326,557 shares of the company’s stock, valued at $79,670,111.29. The trade was a 13.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 73,187 shares of company stock valued at $17,790,912. Corporate insiders own 10.80% of the company’s stock.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be issued a $0.55 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. Cencora’s dividend payout ratio is currently 29.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.